Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
08:02pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment community
3 Pharmaceutical Stocks With Awesome Futures
11:15am, Saturday, 09'th Apr 2022 The Motley Fool
The market is so pessimistic about anything COVID-related that everything has gotten super cheap.
3 Pharmaceutical Stocks With Awesome Futures
07:15am, Saturday, 09'th Apr 2022
The market is so pessimistic about anything COVID-related that everything has gotten super cheap.
The Zacks Analyst Blog Highlights Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals
03:32pm, Friday, 08'th Apr 2022 Zacks Investment Research
Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.
Antibody Treatments for COVD-19 Face Challenges in the U.S.
01:31pm, Friday, 08'th Apr 2022 Zacks Investment Research
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
Antibody Treatments for COVD-19 Face Challenges in the U.S.
10:32am, Friday, 08'th Apr 2022
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
Biotech Stock Roundup: VIR Down on Regulatory News, BMY Offers Updates & More
05:23pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.
VIR Stock Down on Another Setback for COVID-19 Antibody
04:25pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
04:14pm, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
SAN FRANCISCO, April 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric COVID-1
How to Find New Stocks for Your Portfolio
02:00pm, Wednesday, 06'th Apr 2022 The Motley Fool
I like to read articles by people who aren't just bullish -- they've bought shares.
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
08:02pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare Con
Why Shares of Vir Biotechnology Rose 20.4% This Week
04:43pm, Friday, 01'st Apr 2022 The Motley Fool
Joining the S&P SmallCap 600 could boost the company's profile.
Why Shares of Vir Biotechnology Rose 20.4% This Week
12:43pm, Friday, 01'st Apr 2022
Joining the S&P SmallCap 600 could boost the company's profile.
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
07:10pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
04:33pm, Thursday, 31'st Mar 2022
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
